Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for Plasmid Amplification and Purification – V 2.0

Posted on By


Biosimilars: SOP for Plasmid Amplification and Purification – V 2.0


Standard Operating Procedure for Plasmid Amplification and Purification in Biosimilar Development

Department Biosimilars
SOP No. SOP/BS/006/2025
Supersedes SOP/BS/006/2022
Page No. Page 1 of 12
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define the process for amplifying and purifying plasmid DNA from transformed bacterial cells to ensure high-quality DNA yield suitable for downstream biosimilar applications.

2. Scope

This SOP applies to research personnel in the Biosimilars department involved in plasmid preparation for gene expression, cloning, and sequence verification activities.

3. Responsibilities

  • Research Associate: Executes bacterial growth and plasmid extraction.
  • Laboratory Technician: Prepares media, stocks, and handles centrifugation and filtration steps.
  • QA Officer: Reviews purity and concentration documentation.

See also  Biosimilars: SOP for Restriction Enzyme Digestion and Mapping - V 2.0

4. Accountability

The Head of Biosimilars Molecular Biology is accountable for ensuring plasmid preparation is carried out per defined standards and the DNA meets required specifications.

5. Procedure

5.1 Inoculation and Culture

  1. Inoculate a single colony of transformed E. coli into 5 mL of LB broth with appropriate antibiotic.
  2. Incubate at 37°C with shaking (200 rpm) overnight.

5.2 Plasmid Amplification

  1. Transfer overnight culture into 100 mL LB broth with antibiotic.
  2. Incubate at 37°C with shaking for 8–10 hours until OD600 reaches 2.0–2.5.

5.3 Harvesting Bacterial Cells

  1. Transfer culture to centrifuge bottles and spin at 6,000 rpm for 10 minutes at 4°C.
  2. Discard supernatant and proceed with plasmid extraction immediately or store pellet at -20°C.

5.4 Plasmid Purification

  1. Use a commercial plasmid purification kit (e.g., Qiagen, Thermo Fisher).
  2. Follow standard alkaline lysis procedure:
    • Resuspend in Buffer P1
    • Lyse with Buffer P2
    • Neutralize with Buffer N3
  3. Centrifuge at 13,000 rpm for 10 minutes to pellet debris.
  4. Apply supernatant to spin column and wash with ethanol-based buffer.
  5. Elute plasmid in nuclease-free water or TE buffer (50–100 µL).
See also  Biosimilars: SOP for mRNA Transcript Analysis (RT-PCR) - V 2.0

5.5 DNA Quantification and Quality Check

  1. Measure DNA concentration using NanoDrop or equivalent spectrophotometer.
  2. Check purity using A260/A280 ratio (acceptable: 1.8–2.0).
  3. Record all data in Plasmid Quality Log (Annexure-1).

5.6 Agarose Gel Verification

  1. Run 5 µL of plasmid DNA on 1% agarose gel with loading dye.
  2. Visualize bands under UV transilluminator.
  3. Confirm correct plasmid size and supercoiled form.

5.7 Documentation and Storage

  1. Label purified plasmid tubes with ID, date, and concentration.
  2. Store at -20°C or -80°C depending on long-term use.
  3. Update Plasmid Storage Inventory (Annexure-2).

6. Abbreviations

  • SOP: Standard Operating Procedure
  • OD600: Optical Density at 600 nm
  • TE: Tris-EDTA Buffer
  • QA: Quality Assurance

7. Documents

  1. Plasmid Quality Log (Annexure-1)
  2. Plasmid Storage Inventory (Annexure-2)
See also  Biosimilars: SOP for Southern Blot Analysis - V 2.0

8. References

  • ICH Q5B – Analysis of Expression Constructs
  • WHO Technical Report Series 978 – Annex on DNA Products
  • CDSCO Guidelines for Molecular Biology Procedures

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Plasmid Quality Log

Date Plasmid ID Concentration (ng/µL) A260/A280 Purity Status Tested By
02/05/2025 pCMV-rhEPO 205 1.92 Accepted Sunita Reddy

Annexure-2: Plasmid Storage Inventory

Plasmid ID Date Volume (µL) Location Stored By
pCMV-rhEPO 02/05/2025 80 Freezer R-2 (-20°C) Rajesh Kumar

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Expanded section on agarose gel confirmation and added storage tracking Annual review
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: API Manufacturing: SOP for Work-Up Procedure After Reaction Completion – V 2.0
Next Post: BA-BE Studies: SOP for Scheduling of Pre-Dose Fasting Period – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version